• Inventage Lab received the Phase 1 clinical study report for IVL3004 and IVL4002 on Oct. 31, 2026.
• IVL3004 targets alcohol and opioid dependence; IVL4002 targets multiple sclerosis. The Australian study enrolled healthy adults.
• Most adverse events with IVL3004 were mild; injection-site reactions resolved faster than with Vivitrol.
• IVL4002 showed favorable safety and tolerability. Both candidates demonstrated sustained drug exposure supporting monthly dosing.
• Topline results were disclosed Sept. 10, 2025; the latest findings are planned for future conference presentations and investor materials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventage Lab Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900345), on November 02, 2026, and is solely responsible for the information contained therein.